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Abstract
Objectives: SARS-CoV-2, causing COVID-19, has emerged
to cause a human pandemic. Detection of SARS-CoV-2 in
respiratory samples by using PCR is the standard labora-
tory diagnostic tool. Our aim was to perform a limited
evaluation of the diagnostic performance and user-
friendliness of eleven rapid tests for detection of anti-
bodies against SARS-CoV-2.
Methods: All participants were tested with PCR against
SARS-CoV-2 at a clinical microbiology laboratory.
Comparing with results from PCR tests, we evaluated the
rapid tests’ performances in three arms; 1) 20 hospitalized
patients with PCR-confirmed COVID-19, 2) 23 recovered
outpatients with former PCR-confirmed COVID-19, and 3)
49 participants with suspected COVID-19 presenting at a
primary care emergency room.
Results: All eleven tests detected antibodies in hospital-
ized COVID-19 patients, though with varying sensitivities.
In former outpatients recovered from COVID-19, there were
differences between tests in the immunoglobulin type G
(IgG) sensitivity, with five tests having a sensitivity below
65%. In participants with suspected COVID-19 infection,
the rapid tests had very low sensitivities. Most rapid tests
were easy to perform and interpret.
Conclusions: Rapid tests were not suited as stand-alone
tests to detect present infection in a Norwegian primary
care emergency room population. All the rapid tests were
able to detect SARS-CoV-2 antibodies, although sensitiv-
ities varied and were generally higher in the study arm of
more severely affected participants. Rapid tests with high
IgG sensitivity (and specificity) may be useful for confir-
mation of past infection. An independent evaluation
should be performed in the intended population before
introducing a rapid test.
Keywords: antibody detection; COVID-19; point of care;
rapid tests; SARS-CoV-2; sensitivity.
Introduction
In December 2019, Wuhan city in Hubei Province, China,
became the center of an outbreak of a severe pneumonia,
later named Coronavirus Disease 2019 (COVID-19), and
identified as caused by a novel coronavirus SARS-CoV-2
[1]. The coronavirus was isolated, and full-genome
sequencing showed a betacoronavirus in the subgenus
sarbecovirus [2]. Human-to-human transmission of
SARS-CoV-2 occurs primarily through respiratory drop-
lets. Due to the rapid spread of the virus, theWorld Health
Organization declared COVID-19 a worldwide pandemic
by February 2020. The clinical presentation of COVID-19
varies from asymptomatic disease, via mild upper respi-
ratory infection to severe pneumonia with respiratory
failure and death.
Molecular diagnostic tests with real-time PCR are used
to identify SARS-CoV-2 RNA in respiratory samples. PCR is
performed at medical microbiology laboratories, requiring
advanced analytical instruments and trained personnel.
Shortage of sampling equipment and necessary reagents
has periodically limited the number of people being tested
for COVID-19 in Norway.
Detecting humoral immune response to the virus is a
different analytical approach. Generally, immunoglobulin
type M (IgM) is produced during the early stages of an
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infection, usually followed by production of immuno-
globulin type G (IgG). For infection with SARS-CoV-2,
however, there is some evidence that IgG may be detected
at the same time as IgM, or even earlier [3, 4]. Several
enzyme immune assays (EIA) or chemiluminescent im-
munoassays (CLIA) for detection of antibodies against
SARS-CoV-2, both commercial and in-house, will are
becoming available in Norwegian hospital laboratories. At
the same time, a substantial number of point-of-care rapid
tests (lateral flow immunoassays) are currently being
marketed. Even though most of the rapid tests are CE/IVD
approved, they generally come with very limited docu-
mentation on test performance, and only rarely with any
manufacturer independent evaluation [5–7].
Our aim was to perform a limited evaluation of the
diagnostic performance of a selection of rapid test for
COVID-19 in different clinical settings, and in particular to
evaluate if the tests could be used to confirm past infection.
Further, we wanted to assess user-friendliness.
Materials and methods
The evaluation was organized as a quality assurance study in a
collaborative effort between the municipality of Kristiansand, the
Norwegian Institute of Public Health, and the Norwegian Organi-
zation for Quality Improvement of Laboratory Examinations
(Noklus). The eleven rapid tests chosen for evaluation were a con-
venience sample, consisting of the tests that could be delivered to
Noklus before the set deadline of April 1st, 2020 (Table 1). Suppliers
provided their tests free of charge to Noklus and did not pay for the
evaluation. In sending the tests, they consented to having the results
published.
The rapid tests were for professional use and designed to quali-
tatively detect IgM and/or IgG antibodies against SARS-CoV-2, with
results read visually after 10–15min. All rapid tests were performed by
experienced biomedical laboratory scientists and in accordance with
manufactures’ instructions (Supplemental Table) under optimal and
standardized conditions, using venous blood samples with K2-EDTA
anticoagulant. A test was considered invalid if the control line did not
appear, and inconclusive if it was not possible to read the result (for
instance due to blood drawn into the test area).
Patients were enrolled in three study arms: 1) 20 patients with
PCR-confirmed COVID-19, hospitalized at Oslo University Hospital,
Ullevål, 2) 23 recovered outpatients in themunicipality of Kristiansand
with previously PCR-confirmed COVID-19, and 3) 49 patients with
suspectedCOVID-19 presenting at the primary care emergency roomof
Bergen municipality. All patients were tested with rapid test for
detection of antibodies, and with PCR against SARS-CoV-2 in samples
fromupper airways. In studyarm 1, rapid test analyseswere performed
on surplus K2-EDTA whole blood left over from hematology analyses.
In study arms 2 and 3, participants consented to having one tube of K2-
EDTA whole blood drawn for the analyses. In study arms 1 and 2,
PCR-confirmedCOVID-19was the inclusion criterion, but in arm3, PCR
results were collected in addition to the rapid test results. We also
collected the date and laboratory used for the PCR test, and the
number of days since onset of symptoms (in arm one in categories <7,
7–13 and 14+ days).
PCR results from the clinicalmicrobiology laboratories were used
as comparison when investigating diagnostic accuracy of the rapid
tests. IgM and IgG test results were evaluated separately, except for
test E, which detected “total antibodies”. In all study arms, we
calculated the tests’ sensitivities (positivity rates). Sensitivity was
defined as the proportion of patients with antibodies detectable by the
rapid test among those with PCR-confirmed COVID-19. In study arm 3,
we also calculated the proportion of participants with negative PCR
testswhowere antibodynegative. Further, in study arm3,we stratified
positivity rates according to days since onset of symptoms (<7 or
7+ days). Because sample sizes were small, we computed 80% con-
fidence intervals for binomial proportions, and we used the adjusted
Wald method (8).
User-friendliness was reported by the biomedical laboratory
scientists performing the tests.
Ethical considerations
This was a quality assurance study, and we used anonymized data.
The project was approved by the data protection officer at each test
site. Informed verbal consent was obtained from the patients in study
arms two and three at collection of blood samples.
Table : Rapid tests included in evaluation.
Test acronym Test name Manufacturer
A Acro -nCoV IgG/IgM Rapid Test Acro Biotech Inc, USA
B OnSite Covid- IgG/IgM Rapid Test CTK Biotech, Inc, USA
C COVID- IgG/IgM Rapid Test Kit WuHanUNscience Biotechnology Co., China
D A Rapid IgM-IgG Combined Antibody Test Kit for SARS-CoV- Jiangsu Medomics medical technology Co., China
E Wantai SARS-CoV- Ab Rapid Test Kit Beijing Wantai Biological Pharmacy Enterprise Co, China
F Novel coronavirus -nCov) IgM/IgG Antibody Combo Test Kit Hangzhoue Laihe Biotech Co, China. (LYHER)
G Novel Coronavirus (SARS-CoV-) IgM Antibody Detection Ki RayBiotech, USA
H Novel Coronavirus (SARS-CoV-) IgG Antibody Detection Kit RayBiotech, USA
I Lumiratek COVID- IgG/IgM Hurtigtest kassett Hangzhou Biotest Biotech Co., China
J Covid- IgG/IgM Rapid Test Cassette SureScreen Diagnostics, UK
K SARS-CoV- IgG/IgM Rapid Test Zhuhai Encode Medical Engineering Co., China
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Results
In the 20 hospitalized patients in study arm 1, the
number of days since onset of symptoms was <7 for one
patient, 7–13 days for three patients, and 14+ days for 16
patients. In study arms 2 and 3, the median number of
days since onset of symptoms was 30 (range 27–36) and
8 (range 2–34), respectively. Of the 23 participants in
study arm 3with a positive PCR test, thirteen had <7 days
since onset of symptoms, six had 7–13 days, and four
had 14+ days.
Results fromhospitalized patients (study arm 1) showed
that all the eleven rapid tests detected SARS-CoV-2 IgM and/
or IgG antibodies in this population, though with varying
sensitivities (Tables 2 and 3). Study arm two consisted of
participants who had recovered from PCR-confirmed
COVID-19 without requiring hospitalization. In this popu-
lation, tests A, B, C, and D had higher IgG positivity rates
than tests E, F, H I, and J. Confidence intervals (80%) for test
Kwere overlappingwith the others (Table 3). Fiveof the tests
had a sensitivity below 65% for IgG.
Of the 49 participants with suspected COVID-19 (study
arm 3), 23 had positive PCR tests, and 26 tested negative. In
this population, the rapid tests had very low sensitivities
when compared to PCR (Tables 2 and 3). Positivity rates
increased with increasing number of days since onset of
symptoms, especially for IgM (Table 4). However, even for
IgM, none of the tests had a positivity rate above 50%
among patients with confirmed COVID-19 and less than
14 days of symptoms, although numbers were too small to
draw firm conclusions. Few rapid tests were positive in
participants with negative PCR tests.
Not all participants with PCR confirmed COVID-19 had
detectable SARS-CoV-2 antibodies. Also, despite compara-
ble sensitivities, the rapid tests did not necessarily give the
same result in all participants (Supplemental Figures 1–3).
For test K, IgM and IgG results were identical in all partici-
pants in study arms 1 and 2, and in 46 out of 49 participants
Table : Test results, IgG.
Study arm  (n=) Study arm  (n=)a Study arm  (n=)b
Sensitivity Sensitivity Sensitivity Proportion PCR negative without detectable antibodies
A . (.–.) . (.–.) . (.–.) . (.–.)
B . (.–.) . (.–.) . (.–.) . (.–.)
C . (.–.) . (.–.) . (.–.) . (.–.)
D . (.–.) . (.–.) . (.–.) . (.–.)
Ec . (.–.) . (.–.) . (.–.) . (.–.)
F . (.–.) . (.–.) . (.–.) . (.–.)
H . (.–.) . (.–.) . (.–.) . (.–.)
I . (.–.) . (.–.) . (.–.) . (.–.)
J . (.–.) . (.–.) . (.–.) . (.–.)
K . (.–.) . (.–.) . (.–.) . (.–.)
an for test C: . bn for test C: , for test D: , for test H: . cTotal antibodies. Arm  – Oslo University Hospital, Ullevål. Arm  – Kristiansand
municipality. Arm  – Bergen municipality primary care emergency room.
Table : Test results, IgM.
Study arm  (n=) Study arm  (n=)a Study arm  (n=)b
Sensitivity Sensitivity Sensitivity Proportion PCR negative without detectable antibodies
A . (.–.) . (.–.) . (.–.) . (.–.)
B . (.–.) . (.–.) . (.–.) . (.–.)
C . (.–.) . (.–.) . (.–.) . (.–.)
D . (.–.) . (.–.) . (.–.) . (.–.)
F . (.–.) . (.–.) . (.–.) . (.–.)
G . (.–.) . (.–.) . (.–.) . (.–.)
I . (.–.) . (.–.) . (.–.) . (.–.)
J . (.–.) . (.–.) . (.–.) . (.–.)
K . (.–.) . (.–.) . (.–.) . (.–.)
an for test D: . bn for test C: , for test D: , for test G: . Arm  – Oslo University Hospital, Ullevål. Arm  – Kristiansand municipality.
Arm  – Bergen municipality primary care emergency room.
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in arm 3. Tests F, I and J had higher positivity rates for IgM
than IgG in study arm 2, even though all samples were
collected more than 14 days after onset of symptoms.
Tests G and H were judged as less user-friendly (Ta-
ble 5), both when performing the tests and interpreting the
results. These tests also had higher proportions of incon-
clusive or invalid results. Tests C and Ewere judged easy to
perform but difficult to interpret. Test C additionally had a
high proportion of inconclusive or invalid results.
Discussion
All the evaluated rapid tests detected SARS-CoV-2 anti-
bodies in participants with PCR-confirmed COVID-19,
although positivity rates varied and were generally
higher in the study arm of more severely affected patients.
In the population with suspected COVID-19, none of the
rapid tests had any diagnostic value, but further studies are
needed to assess the usefulness of antibody rapid tests in
the acute phase of COVID-19 as a supplement to PCR.
PCR for detection of viral RNA and antibody detection
tests use different test principles and are not interchange-
able. The viral load in upper or lower respiratory tract is
highest in early stages of COVID-19, while it takes several
days for the adaptive immune system to elicit an antibody
response. Early in the infection, we therefore expect PCR to
be positive and antibody detection tests to be negative. As
the infection progresses and clears, most patients will
develop detectable antibodies, while the virus is gradually
cleared from the upper airways [9]. Thus, even under the
best of circumstance, PCR is far from an ideal “gold stan-
dard” for comparison of antibody detecting rapid tests.
If a participant with PCR-confirmed COVID-19 has no
detectable antibodies, there are several possibilities: (i) the
stage of the infection is too early for antibodies to have
been formed, (ii) the level of antibodies produced is too low
to be detected, (iii) the participant does not produce anti-
bodies, (iv) a false negative rapid test result, or v) a false
positive PCR result (wrong labeling for instance). Similarly,
if a participant with negative SARS-CoV-2 PCR has detect-
able antibodies on a rapid test, there are a number of
plausible explanations: (i) the participant is recovering
from COVID-19 and had cleared the virus prior to PCR
testing, ii) false positive rapid test result (for instance cross
reaction with other antibodies), or (iii) false negative PCR
result (pre-analytical or analytical issues). Comparing re-
sults from several rapid tests with each other may provide
some clue as towhich is themost likely explanation in each
case, but does not provide a definite answer.
To determine a rapid test’s ability to detect past
infection, its performance with regard to IgG antibodies is
emphasized in the specification criteria for serology point
of care tests published by the United KingdomMedicines &
Healthcare products Regulatory Agency [10]. Most of the
included rapid tests had higher IgG positivity rates in arm 1
(hospitalized patients) than in arm 2 (recovered out-
patients). More severe infection has been associated with
higher levels of antibodies [3, 4]. One might speculate that
antibody levels were lower in study arm 2, where partici-
pants were less severely affected compared to the hospi-
talized patients in study arm 1. This may have influenced
rapid test performance. It is worth noticing that according
tomanufacturers’ information; most of the rapid tests have
been evaluated in samples collected from hospitalized
populations. We were not able to evaluate the tests’
Table: Sensitivity stratifiedby number of days since onset of symptoms for patients in study armwith positive PCR results (mediandays).
Test IgM IgG
< days (n=) + days (n=) < days (n=) + days (n=)
A . (.–.) . (.–.) . (.–.) . (.–.)
B . (.–.) . (.–.) . (.–.) . (.–.)
C . (.–.) . (.–.) . (.–.) . (.–.)
D . (.–.) . (.–.) . (.–.) . (.–.)
Ea . (.–.) . (.–.)
F . (.–.) . (.–.) . (.–.) . (.–.)
G . (.–.) . (.–.)
H . (.–.) . (.–.)
I . (.–.) . (.–.) . (.–.) . (.–.)
J . (.–.) . (.–.) . (.–.) . (.–.)
K . (.–.) . (.–.) . (.–.) . (.–.)
aTotal antibodies.
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performances in a population that had been through
COVID-19 with very little or no symptoms.
In study arm 3, most participants had a short duration
of symptoms. In this population, all of the rapid tests in our
study had low sensitivities compared to PCR, confirming a
priori expectations. It is possible that the rapid tests, and
IgM in particular, may still have a supplemental role in
diagnosing COVID-19 in the acute phase. However, among
patients with confirmed COVID-19 and less than 14 days of
symptoms, none of the tests in our study had a positivity
rate above 50%. Thus, the diagnostic value of using any of
these tests during the first two weeks of infection seems
very low. Furthermore, a negative result in the acute phase
of infection should be followed by a second sample at least
14 days after onset of symptoms, and it is imperative that a
negative result of a rapid test is never be used to exclude
COVID-19.
In study arm 3, we also calculated the proportion of
participants with negative PCR tests who did not have
detectable antibodies. We do not know if a participant with
a negative PCR test and a positive IgG rapid test has, or has
recovered from, COVID-19, or if the rapid test result is a
false positive. In a population where the prevalence of
COVID-19 is low, there could be a substantial a risk of false
positive results, which we cannot at present quantify
because of the lack of knowledge of the tests’ specificities.
Nevertheless, it is worth noticing that the few positive test
results among patients with negative PCR and short dura-
tion of symptoms, were mainly IgM. In any case, an iso-
lated positive IgM result should be followed by a second
sample to detect IgG-seroconversion and thereby rule out
the possibility of an unspecific IgM result.
The strengths of our study include the large number of
rapid tests included, and the varied clinical settings we
were able to evaluate the tests in. The small sample size is
an important limitation, meaning our results must be
interpretedwith caution, particularlywhen considering the
different groups and the time from the onset of symptoms.
Also, PCR is not an ideal gold standard when evaluating
antibody detecting rapid tests. Finally, the lack of pre-
COVID-19 sera limited our ability to assess false positives
and the tests’ specificities. Asmore rapid tests are emerging
and EIA becomes increasingly available, our group will
continue to evaluate tests. We will use EIAmethodology as
a comparison method in addition to PCR, and also analyze
sera collected before the COVID-19 pandemic. This will
allow us to investigate diagnostic accuracy and analytical
properties of the rapid tests more thoroughly.
Table : User-friendliness and inconclusive/invalid tests.
Test acronym User-friendliness Inconclusive tests, IgM Inconclusive tests, IgG
n (arm ,,) n (arm ,,)
A Easy to perform test. ,, ,,
Easy to read results.
B Hard to avoid air bubbles in buffer vial. Light pink background not optimal
for reading weak positive results.
,, ,,
C Ran out of buffer early at one test site. Difficult to read result due to colored
background. Blood drawn into the IgM test area. % invalid/incon-
clusive tests.
,, ,,
D Easy to perform test. ,, ,,
Easy to read results.
Ea Easy to perform test. Strong pink backgroundmade it difficult to readweak
positive results.
NA ,,
F Easy to perform test. ,, ,,
Easy to read results.
G Buffer vial spills easily. Requires mixing of blood and buffer pre analyses
and a pipette for analyses. Difficult to read results due to blood drawn
into the test area. % invalid/inconclusive tests.
,, NA
H Buffer vial spills easily. Requires mixing of blood and buffer pre analyses
and a pipette for analyses. Difficult to read results due to blood drawn
into the test area. % invalid/inconclusive tests.
NA ,,
I Easy to perform test. ,, ,,
Easy to read results.
J Easy to perform test. ,, ,,
Easy to read results.
K Easy to perform test. ,, ,,
Easy to read results.
aTotal antibodies.
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Conclusions
Based on our observations, results from rapid test for
detection of antibodies seem to be unreliable during the
first two weeks of symptoms of COVID-19. However, rapid
tests with a high IgG sensitivity may be useful for confir-
mation of past infection. We also recommend using tests
that are user-friendly and have a low proportion of invalid/
inconclusive tests. In our study, it seems that tests A, B, D,
and possibly K (Table 1) fulfill these recommendations,
under the assumption that their specificities are high.
To allow sufficient time to develop antibodies, we recom-
mend not using a rapid test until at the earliest twoweeks after
onset of symptoms. Anegative testmaybe repeated, but not all
SARS-CoV-2 infecteddevelopantibodies, andnot all antibodies
arenecessarilydetectedby the rapid test. Thus,anegative rapid
antibody test does not rule out current nor past COVID-19.
Finally, we recommend performing an independent
evaluation before introducing a new rapid test, and impor-
tantly, in thepopulation it is intendedfor.Our results indicate
that when a rapid test is to be used to detect past infection in
people who have not required hospitalization, it is not suf-
ficient to validate the test in a hospitalized population.
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